Sign In
Buy ILMN
$170.93
+8.38 (+5.16%)
At Close: Jun 03, 2026
Illumina Buys Fluent BioSciences To Gain Stronger Foothold In Single-Cell Analysis
01:05pm, Wednesday, 10'th Jul 2024
Last month, Illumina Inc ILMN had to let go of Grail Inc. Still, the DNA sequencing company has acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research.
Illumina (ILMN) Buys Fluent, Grows in Single Cell Research
11:55am, Wednesday, 10'th Jul 2024
By integrating Fluent's unique technology with Illumina's (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a comprehensive solution for single-cell multiomic analy
Illumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base
04:05pm, Tuesday, 09'th Jul 2024
Accessible, highly scalable single-cell technology expands Illumina's multiomics capabilities SAN DIEGO , July 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencin
3 Biotech Stocks Turning DNA Dreams Into Dollars
06:55am, Friday, 05'th Jul 2024
When discussing biotechnology, many focus on medication based on biochemical compounds and their downstream effects. Yet several branches of medical genetics and therapeutics have begun to find novel
The 3 Best Personalized Medicine Stocks to Buy in July 2024
07:00am, Wednesday, 03'rd Jul 2024
The personalized medicine market is experiencing significant growth, driven by advancements in genomic technologies and a shift towards more individualized healthcare. In 2024, the market is expected
Illumina Takes a $1.47 Billion Charge Related to Its Spinoff of GRAIL
11:56am, Friday, 28'th Jun 2024
The breakup with GRAIL (GRAL) was costly for Illumina (ILMN).
Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out
04:35am, Friday, 28'th Jun 2024
Illumina has finally completed the divestiture of GRAIL, ending a disastrous chapter in its history. The Company paid $8bn to acquire the cancer testing business it helped to create, which proved to b
Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2
05:26pm, Thursday, 27'th Jun 2024
Illumina said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to the recently spun-off Grail Inc.
Illumina Completes Spin-Off Of GRAIL
02:18pm, Wednesday, 26'th Jun 2024
On June 25, 2024, Illumina, Inc. (NASDAQ: ILMN, $208.92, Market Capitalization: $18.51 billion) announced the completion of the tax free spin-off of GRAIL, Inc. (NASDAQ: GRAL, $36.84, Market Capitaliz
Illumina (ILMN) Rises on Conclusion of GRAIL Divestment
12:30pm, Tuesday, 25'th Jun 2024
With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.
GRAL Stock Alert: 7 Things to Know as Grail Starts Trading Today
11:12am, Tuesday, 25'th Jun 2024
The world of biotech stocks got a new member today. Grail (NASDAQ: GRAL ) has successfully completed its spinoff from industry leader Illumina (NASDAQ: ILMN ).
Grail's shares fall in Nasdaq debut after spin-off from Illumina
09:41am, Tuesday, 25'th Jun 2024
Shares of Grail fell as much as 11.7% in their market debut on Tuesday after being spun out of gene-sequencing company Illumina.
Grail bets big on flagship cancer test after spin-off from Illumina
04:50pm, Monday, 24'th Jun 2024
U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina , is betting that commercial partnerships with health systems, employers a
Illumina completes the divestiture of GRAIL
04:05pm, Monday, 24'th Jun 2024
GRAIL spin-off complete; GRAIL to begin regular way trading as "GRAL" on June 25 Illumina to issue second quarter 2024 results on August 6; leadership to present Strategy Update on August 13 SAN DIEGO
The Watchlist: 3 Stock Spinoffs Coming Soon (Be Ready to Buy)
06:15am, Monday, 17'th Jun 2024
Stock spinoffs to buy can be tricky finds. They represent opportunities to cash in on a business that oftentimes gets lost in the shuffle of competing for resources with other corporate initiatives.
